PANOQUELL-CA1 Fuzapladib Sodium for Injection

PANOQUELL-CA1 is a fuzapladib-sodium freeze-dried injection preparation. Its referenced US product information addresses clinical signs associated with acute-onset pancreatitis in dogs, within a veterinary treatment plan.

A specific inflammatory-cell pathway

The reference describes fuzapladib as a leukocyte function-associated antigen-1 activation inhibitor. This helps explain its place in the referenced pancreatitis setting. The dog’s clinical condition and the full care plan determine its use; a product description does not replace that assessment.

Drug content and liquid volume differ

The US-labelled reference vial contains 14 mg of fuzapladib sodium, with a labelled concentration of 4 mg/mL after reconstitution. Those figures are distinct from a 14 mL bottle volume. Identify the required market pack and full vial label when comparing the item.

Professional preparation matters

This is a powder-for-injection preparation administered intravenously by a veterinary professional. The supplied diluent, preparation instructions and storage periods are part of the exact product label. Instructions for a different fuzapladib vial should not be transferred by ingredient name.

An enquiry should name the presentation

Keep the brand, market label and vial content with the clinical team’s product details. Japanese and US packaging references should be distinguished. This helps identify the required pack without assuming that a similar photograph establishes the same supplied formulation.